^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AP203

    i
    Other names: AP203, AP 203, AP-203
    Associations

    News

    Trials
    Company:
    AP Biosciences
    Drug class:
    PD-L1 inhibitor, CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity. (PubMed, J Transl Med)
    AP203 exerts potent antitumor activity not only by blocking PD-1/PD-L1 inhibitory signaling, but also by activating CD137 costimulatory signaling in effector T cells that consequently counteracts Treg-mediated immunosuppression. Based on promising preclinical results, AP203 should be a suitable candidate for clinical treatment of solid tumors.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    PD-L1 expression
    |
    AP203
    over2years
    APT-CUBE: A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies (clinicaltrials.gov)
    P1/2, N=168, Not yet recruiting, AP Biosciences Inc.
    New P1/2 trial
    |
    BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    PD-L1 expression • BRAF V600E • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • MET mutation • RET rearrangement • NTRK1 mutation • NTRK3 mutation
    |
    AP203